Rubinan, P, Viñado, B, Fernández-Hidalgo, N, Larrosa, N, Sempere, A, Campany, D, Rodríguez-Pardo, D, González-López, JJ, Nuvials, X, del Barrio-Tofiño, E, Escolà-Vergé, L, Los-Arcos, I. Ciprofloxacin for the Treatment of Infections Caused by Carbapenemase-Producing Gram-Negative Bacteria. Antibiotics-Basel. 2024; 13(12)DOI:10.3390/antibiotics13121138. PMID:39766528. IF:4.600(Q1/2D).

Moreno-Rubio, E, Pérez-López, C, Carmezim, J, Blancas-Altabella, D, Simonetti, AF, Sanchez, SS, Rodríguez-Molinero, A. Adequacy of the Type of Venous Catheter to the Drug Type and Duration of Treatment: A Cross-Sectional Study. Nursing Reports. 2026; 16(2)DOI:10.3390/nursrep16020076. PMID:41745901. IF:(Q/D).

Morcillo-Nieto, AO, Zsadanyi, SE, Arriola-Infante, JE, Carmona-Iragui, M, Montal, V, Pegueroles, J, Aranha, MR, Vaque-Alcazar, L, Padilla, C, Benejam, B, Videla, L, Barroeta, I, Fernandez, S, Altuna, M, Gimenez, S, Gonzalez-Ortiz, S, Bargallo, N, Ribas, L, Arranz, J, Torres, S, Iulita, MF, Belbin, O, Camacho, V, Alcolea, D, Lleo, A, Fortea, J, Bejanin, A. Characterization of white matter hyperintensities in Down syndrome. ALZHEIMERS & DEMENTIA. 2024; 20(9)DOI:10.1002/alz.14146. PMID:39087352. IF:11.100(Q1/1D).

Ospina, AV, Nadal, SB, de la Cruz, JLCC, Larriba, JLG, Vidueira, IM, Sureda, BM, Nadal, E, Trancho, FH, Kindelan, AA, Morillo, E, Caro, RB, Barrera, JB, de Juan, VC, Rubio, JC, de Castro, J, Ramos, AC, Dols, MC, Gomez, M, Almanzar, S, Campelo, RG, Molla, AI, Sarceda, JRJ, Maestre, UJ, Castro, RL, Majem, M, Martinez-Marti, A, Tellez, EM, Lorente, DS, Provencio, M. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP. Clinical & Translational Oncology. 2024; DOI:10.1007/s12094-024-03382-y. PMID:38530556. IF:2.500(Q3/6D).

Hoffman-Censits, J, Tsiatas, M, Chang, PMH, Kim, M, Zagouri, F, Shin, SJ, Kim, SH, Su, HYL, Arija, JAA, Maroto-Rey, JP, Antonuzzo, L, Maruzzo, M, Tambaro, R, Blais, N, Rottey, S, Gakis, G, Schneider, A, Tyroller, K, Jacob, N, Valderrama, BP. Avelumab (Ave) in combination with other anticancer agents as first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC): Primary analysis from the JAVELIN Bladder Medley phase 2 trial.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(7_SUPPL)DOI:10.1200/JCO.2026.44.7_suppl.739. PMID:. IF:41.900(Q1/1D).

Gregorc, V, Majem, M, Lo Russo, G, Maio, M, Salvagni, S, Gutiérrez-Calderon, V, Gonzalez-Cao, M, Contreras, SS, Koumarianou, A, Bearz, A, Bernabé-Caro, R, Viteri, S, de Sanmamed, MF, Zagouri, F, Bueno, TM, Lazzari, C, Martínez-Recio, S, Giménez-Capitán, A, Zhang, Y, Shan, Y, Zhu, HQ, Zhao, CQ, Shen, HG, Wang, Y, Rosell, R. Fulzerasib plus cetuximab in first-line KRASG12C-mutated nonsmall-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial. LANCET ONCOLOGY. 2026; 27(4)DOI:10.1016/S1470-2045(25)00764-8. PMID:41926959. IF:35.900(Q1/1D).